Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QDPR | P09417 | 1/20 | 0.62 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.61 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.61 |
| ▸ | ESR2 | Q92731 | 14/20 | 0.59 |
| ▸ | ESR1 | P03372 | 9/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.59 |
| ▸ | HTR2C | P28335 | 2/20 | 0.57 |
| ▸ | ESRRB | O95718 | 2/20 | 0.52 |
| ▸ | ESRRG | P62508 | 2/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2271784 | 0.98 | QDPR (0.60) | QDPRSLC18A3SIGMAR1ESR2ESR1 | |
| Bromide SCHEMBL17477290 | 0.98 | QDPR (0.60) | QDPRSLC18A3SIGMAR1ESR2ESR1 | |
| Ethane SCHEMBL28134207 | 0.96 | ESR2 (0.59) | QDPRSLC18A3SIGMAR1ESR2ESR1 | |
| SCHEMBL25936803 | 0.92 | ESR2 (0.55) | QDPRSLC18A3SIGMAR1ESR2ESR1 | |
| SCHEMBL20805968 | 0.87 | HTR3A (0.66) | QDPRESR2 | |
| SCHEMBL1865798 | 0.83 | ESR2 (0.81) | ESR2ESR1CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL1986271 | 0.83 | ESR2 (0.81) | ESR2ESR1CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL3811445 | 0.83 | ESR2 (0.81) | ESR2ESR1CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL3809909 | 0.83 | ESR2 (0.81) | ESR2ESR1CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL4676148 | 0.81 | SLC18A3 (0.67) | QDPRSLC18A3SIGMAR1ESR2ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 400 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119325330-A | Solar cell and preparation method thereof | 天合光能股份有限公司 | 2025-01-17 | — | — | CN | claimed |
| US-20230035133-A1 | [1,2,4]Triazolo[4,3-B]Pyridazines For Use in the Treatment of Proliferative Diseases | ASTRAZENECA AB (SE) | 2023-02-02 | — | — | US | claimed |
| CN-106750303-B | A kind of polyarylether of the group containing methyl piperidine and preparation method thereof | 吉林大学 | 2019-03-19 | — | — | CN | claimed |
| CN-106750303-A | A kind of polyarylether containing methyl piperidine group and preparation method thereof | 吉林大学 | 2017-05-31 | — | — | CN | claimed |
| CN-101484424-A | Therapeutic compounds | HELICON THERAPEUTICS INC (US) | 2009-07-15 | — | — | CN | claimed |
| CN-101193867-A | N-substituted benzimidazolyl c-Kit inhibitors and combinatorial benzimidazole libraries | OSI PHARM INC (US) | 2008-06-04 | — | — | CN | claimed |
| CN-1304929-A | 4-hydroxy-4-phenyl piperidine derivative and medicine containing said derivative | SS PHARMACEUTICAL CO (JP) | 2001-07-25 | — | — | CN | claimed |
| EP-0630887-B1 | 4-(aryl-substituted)-piperidines as neurokinin receptor antagonists | ZENECA LTD (GB) | 1999-07-28 | — | — | EP | claimed |
| US-5654299-A | TREATING RESPIRATORY SYSTEM DISORDER (I.E. ASTHMA) WITH NEUROKININ 2 RECEPTOR ANTAGONIST | ZENECA LIMITED (GB) | 1997-08-05 | — | — | US | claimed |
| EP-0630887-A1 | 4-(aryl-substituted)-piperidines as neurokinin receptor antagonists | ZENECA LIMITED (GB) | 1994-12-28 | — | — | EP | claimed |
| EP-4731223-A1 | MORPHOLINE AND 1,4-OXAZEPANE COMPOUNDS AND ITS USE IN THERAPY | Universitat De Barcelona (ES) | 2026-04-29 | — | — | EP | disclosed |
| CN-120208859-A | Method for synthesizing 4- (piperidin-4-yl) phenol by one-pot method | 山东丰源生物医药科技有限公司 | 2025-06-27 | — | — | CN | disclosed |
| CN-120208859-A | Method for synthesizing 4- (piperidin-4-yl) phenol by one-pot method | 山东丰源生物医药科技有限公司 | 2025-06-27 | — | — | CN | disclosed |
| WO-2025066935-A1 | COMPOUNDS, COMPOSITIONS AND METHODS THEREOF | HEPAITECH (BEIJING) BIOPHARMA TECHNOLOGY CO., LTD. (CN) | 2025-04-03 | — | — | WO | disclosed |
| CN-119325330-A | Solar cell and preparation method thereof | 天合光能股份有限公司 | 2025-01-17 | — | — | CN | disclosed |
| CN-1047291-A | The 2-of anti-ischaemic agent croak pyridine subbase-1-alkanol derivatives | PFIZER (US) | 1990-11-28 | — | — | CN | disclosed |
| EP-0398578-A2 | 2-piperidino-1-alkanol derivatives as antiischemic agents | PFIZER INC. (US) | 1990-11-22 | — | — | EP | disclosed |
| US-4324791-A | DERIVATIVES OF 3,3-DIPHENYL-2-PYRROLIDINONES | A. H. ROBINS COMPANY, INC. (US) | 1982-04-13 | — | — | US | disclosed |
| US-4127579-A | HYPOTENSIVE | E. R. SQUIBB & SONS, INC. (US) | 1978-11-28 | — | — | US | disclosed |
| US-4120969-A | ANALGETIC, ANTIDIARRHEAL ACTIVITY | A. H. ROBINS COMPANY, INCORPORATED (US) | 1978-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230035133-A1 | [1,2,4]Triazolo[4,3-B]Pyridazines For Use in the Treatment of Proliferative Diseases | MKI67, CCNB1, CCNB2 | QDPR 953/4885SLC18A3 4860/4885SIGMAR1 2764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.